JUVMO
Oct 09, 2026
JUVMO Enters the Parkinson’s Disease Treatment Arena: How AbbVie’s First-in-Class Drug Stacks Up Against Today’s Treatments and Tomorrow’s Pipeline?
Summary On September 28, 2026, the FDA approved AbbVie’s JUVMO (tavapadon) as the first selective dopamine D1/D5 receptor agonist for adults with Parkinson’s disease, introducing a new dopaminergic approach after decades dominated by levodopa and D2/D3 agonists. The approval was supported by findings from the T...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
